Isomorphic Labs, the Google-backed AI drug design company, secured a $2.1 billion Series B round led by Thrive Capital, a scale-up signaling intensified competition in AI-driven small-molecule discovery. Reporting says the round also included new and existing investors, moving Isomorphic toward larger-scale development of its IsoDDE engine. The company said it will fund continued development of its drug design engine and advance its therapeutic pipeline toward the clinic, alongside hiring across AI, engineering, drug design, and clinical development. Isomorphic described its model as an integrated drug design and development engine rather than a software product for licensing. For the broader industry, the size and publicity of the round further underscores that capital is concentrating around AI platforms that can pair discovery optimization with downstream clinical execution.